Stora Södergatan 15
Lund 222 23
Sweden
https://www.wntresearch.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 2
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Thomas Andersson Ph.D. | Founder, Chief Scientific Officer, Director & Scientific Advisor | 572k | N/D | 1956 |
Dr. Per Goran Oskar Norlen | Chief Executive Officer | N/D | N/D | 1970 |
Mr. Anders Tidfors | Chief Financial Officer | N/D | N/D | 1964 |
Dr. Kicki Johansson | Chief Operating Officer | N/D | N/D | 1958 |
Mr. Dennis B. Henriksen M.Sc., Ph.D. | Chief Technical Officer | 418,81k | N/D | 1962 |
Mr. Klaus Christensen | Chief Commercial Officer | N/D | N/D | 1968 |
WntResearch AB, a biotech company, develops therapies to prevent the metastatic process. The company develops Foxy-5, a peptide, which is in Phase II clinical trials that reduced the risk of metastasis in patients with colon cancer. It is also developing Box-5, a WNT5A antagonist for the treatment of malignant melanoma, and pancreatic and gastric cancer. The company was incorporated in 2007 and is based in Lund, Sweden.
L'ISS Governance QualityScore di WntResearch AB al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.